New Phase 1 Trial of TRV045: A Potential Breakthrough for Brain Cell Stimulation
CHESTERBROOK, PA —Trevena, Inc. (Nasdaq: TRVN) this week announced the initiation of a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.
New Phase 1 Trial of TRV045: A Potential Breakthrough for Brain Cell Stimulation Read More